Oxford Immunotec Global PLC (OXFD) Sees Large Volume Increase
Shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) saw unusually-high trading volume on Friday . Approximately 73,278 shares traded hands during mid-day trading, an increase of 4% from the previous session’s volume of 70,324 shares.The stock last traded at $8.65 and had previously closed at $8.73.
OXFD has been the topic of a number of research analyst reports. Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, May 4th. BTIG Research reiterated a “buy” rating and issued a $17.00 price objective on shares of Oxford Immunotec Global PLC in a report on Monday, June 27th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of Oxford Immunotec Global PLC in a report on Sunday, June 26th.
The stock has a 50-day moving average price of $8.95 and a 200-day moving average price of $9.97. The stock’s market capitalization is $199.03 million.
Oxford Immunotec Global PLC (NASDAQ:OXFD) last released its quarterly earnings results on Tuesday, May 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.32). The firm earned $17.10 million during the quarter, compared to analysts’ expectations of $16.96 million. The business’s quarterly revenue was up 23.9% on a year-over-year basis. During the same quarter last year, the business earned ($0.31) earnings per share. On average, equities analysts anticipate that Oxford Immunotec Global PLC will post ($1.28) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Oxford Immunotec Global PLC stock. OppenheimerFunds Inc. increased its stake in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) by 0.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,068,967 shares of the company’s stock after buying an additional 5,440 shares during the period. OppenheimerFunds Inc. owned about 4.74% of Oxford Immunotec Global PLC worth $12,293,000 at the end of the most recent reporting period.
Oxford Immunotec Global PLC is a global, commercial-stage diagnostics company focused on developing and commercializing tests for the management of immune-regulated conditions. The Company’s T-SPOT technology platform allows it to measure the responses of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.